The role of polycomb repressive complexes in biliary tract cancer

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 3, 2015, Pages 363-375

  Mayr, Christian ^a   Neureiter, Daniel ^a   Wagner, Andrej ^a   Pichler, Martin ^b,c   Kiesslich, Tobias ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Biliary tract cancer; BMI1; Epigenetics; EZH2; Histone modifications; Polycomb repressive complex

Indexed keywords

POLYCOMB GROUP PROTEIN; ANTINEOPLASTIC AGENT; BMI1 PROTEIN; HISTONE; POLYCOMB REPRESSIVE COMPLEX 2;

APOPTOSIS; BILIARY TRACT CANCER; CELL CYCLE; DOWN REGULATION; EMBRYONIC STEM CELL; GENE SILENCING; HISTONE MODIFICATION; IMMUNOHISTOCHEMISTRY; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SENESCENCE; THERAPY EFFECT; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BILIARY TRACT NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HISTONES; HUMANS; MOLECULAR TARGETED THERAPY; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; RNA INTERFERENCE;

EID: 84923103079     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.986460     Document Type: Review

References (110)

1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383(9935):2168-79
2. Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol 2009;20(1):146-59
3. Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am 2010;24(4):871-84.vii
4. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013;145(6):1215-29
5. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3(1):33-42
6. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362(14):1273-81
7. Patel T. Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol 2011;8(4):189-200
8. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006;45(6):856-67
9. Kiesslich T, Alinger B, Wolkersdorfer GW, et al. Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol 2010;36(1):49-58
10. Kiesslich T, Berr F, Alinger B, et al. Current status of therapeutic targeting of developmental signalling pathways in oncology. Curr Pharm Biotechnol 2012;13(11):2184-220
11. Kiesslich T, Mayr C, Wachter J, et al. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Mol Cell Biochem 2014;396(1-2):257-68
12. Kiesslich T, Neureiter D. Advances in targeting the Hedgehog signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16(2):151-6
13. Isomoto H. Epigenetic alterations associated with cholangiocarcinoma (review). Oncol Rep 2009;22(2):227-32
14. Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol 2013;1(1):3-11
15. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429(6990):457-63
16. Suzuki T, Terashima M, Tange S, Ishimura A. Roles of histone methyl-modifying enzymes in development and progression of cancer. Cancer Sci 2013;104(7):795-800
17. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3(6):415-28
18. Vidal M. Role of polycomb proteins Ring1A and Ring1B in the epigenetic regulation of gene expression. Int J Dev Biol 2009;53(2-3):355-70
19. Bracken AP, Dietrich N, Pasini D, et al. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006;20(9):1123-36
20. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006;441(7091):349-53
21. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010;7(3):299-313
22. Aldiri I, Vetter ML. PRC2 during vertebrate organogenesis: a complex in transition. Dev Biol 2012;367(2):91-9
23. Luis NM, Morey L, Di Croce L, Benitah SA. Polycomb in stem cells: PRC1 branches out. Cell Stem Cell 2012;11(1):16-21
24. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005;20(6):845-54
25. Kuzmichev A, Nishioka K, Erdjument-Bromage H, et al. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of zeste protein. Genes Dev 2002;16(22):2893-905
26. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011;469(7330):343-9
27. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 2002;298(5595):1039-43
28. Margueron R, Li G, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008;32(4):503-18
29. Richly H, Aloia L, Di Croce L. Roles of the polycomb group proteins in stem cells and cancer. Cell Death Dis 2011;2:e204
30. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007;21(5):525-30
31. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012;106(2):243-7
32. Hernandez-Munoz I, Taghavi P, Kuijl C, et al. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell Biol 2005;25(24):11047-58
33. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40(6):741-50
34. Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439(7078):871-4
35. Yamaguchi J, Sasaki M, Sato Y, et al. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 2010;101(2):355-62
36. van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007;52(2):455-63
37. Cui H, Hu B, Li T, et al. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007;170:1370-8
38. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003;423(6937):255-60
39. Vrzalikova K, Skarda J, Ehrmann J, et al. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 2008;134(9):1037-42
40. Liu JH, Song LB, Zhang X, et al. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 2008;97(3):267-72
41. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68(11):4311-20
42. Hayry V, Tynninen O, Haapasalo HK, et al. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol 2008;34(5):555-63
43. Wang H, Pan K, Zhang HK, et al. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008;134(5):535-41
44. Song LB, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009;119(12):3626-36
45. Proctor E, Waghray M, Lee CJ, et al. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One 2013;8(2):e55820
46. Martinez-Romero C, Rooman I, Skoudy A, et al. The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol 2009;219(2):205-13
47. Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22(20):5323-35
48. Shen L, Cui J, Liang S, et al. Update of research on the role of EZH2 in cancer progression. Onco Targets Ther 2013;6:321-4
49. Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 2012;8(1):59-65
50. Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012;13(2):e83-9
51. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008;88(5):459-63
52. Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012;30(3):372-8
53. Abdouh M, Facchino S, Chatoo W, et al. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009;29(28):8884-96
54. Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011;7(5):517-35
55. Cao L, Bombard J, Cintron K, et al. BMI1 as a novel target for drug discovery in cancer. J Cell Biochem 2011;112(10):2729-41
56. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004;113(2):175-9
57. Voncken JW, Roelen BA, Roefs M, et al. Rnf2 (Ring1b) deficiency causes gastrulation arrest and cell cycle inhibition. Proc Natl Acad Sci USA 2003;100(5):2468-73
58. Kang MK, Kim RH, Kim SJ, et al. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 2007;96(1):126-33
59. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011;17(9):2613-18
60. Wu KJ, Yang MH. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connection. Biosci Rep 2011;31(16):449-55
61. Crea F, Fornaro L, Bocci G, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 2012;31(3-4):753-61
62. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005;280(23):22437-44
63. Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011;26(1):19-27
64. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010;35(6):323-32
65. Brockdorff N. Noncoding RNA and Polycomb recruitment. RNA 2013;19(4):429-42
66. Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009;106(28):11667-72
67. Aguilo F, Zhou MM, Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res 2011;71(16):5365-9
68. Yap KL, Li S, Munoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010;38(5):662-74
69. Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007;129(7):1311-23
70. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464(7291):1071-6
71. Padua Alves C, Fonseca AS, Muys BR, et al. Brief report: the lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells 2013;31(12):2827-32
72. Liu DC, Yang ZL. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 2011;207(8):472-8
73. Yamaguchi J, Sasaki M, Harada K, et al. Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin. Lab Invest 2009;89(9):1018-31
74. Nakagawa S, Okabe H, Sakamoto Y, et al. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol 2013;20(Suppl 3):S667-75
75. Sasaki M, Yamaguchi J, Itatsu K, et al. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol 2008;215(2):175-83
76. Sasaki M, Matsubara T, Kakuda Y, et al. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma. Am J Surg Pathol 2014;38(3):364-9
77. Sasaki M, Ikeda H, Itatsu K, et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 2008;88(8):873-82
78. Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007;20(6):701-9
79. Sasaki M, Yamaguchi J, Ikeda H, et al. Polycomb group protein Bmi1 is overexpressed and essential in anchorage-independent colony formation, cell proliferation and repression of cellular senescence in cholangiocarcinoma: tissue and culture studies. Hum Pathol 2009;40(12):1723-30
80. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275(5308):1943-7
81. Sriraksa R, Zeller C, Dai W, et al. Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer Prev Res (Phila) 2013;6(12):1348-55
82. Leelawat K, Keeratichamroen S, Leelawat S, et al. CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2. Oncol Lett 2013;6(5):1439-46
83. Glazer RI, Knode MC, Tseng CK, et al. 3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem Pharmacol 1986;35(24):4523-7
84. Simon JA. Stopping a chromatin enzyme. Nat Chem Biol 2012;8(11):875-6
85. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21(9):1050-63
86. Benoit YD, Laursen KB, Witherspoon MS, et al. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. J Cell Physiol 2013;228(4):764-72
87. Gannon OM, Merida de Long L, Endo-Munoz L, et al. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer Res 2013;19(2):428-41
88. Puppe J, Drost R, Liu X, et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 2009;11(4):R63
89. Hayden A, Johnson PW, Packham G, et al. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat 2011;127(1):109-19
90. Cheng LL, Itahana Y, Lei ZD, et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res 2012;18(15):4201-12
91. Kikuchi J, Takashina T, Kinoshita I, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012;78(2):138-43
92. Alimova I, Birks DK, Harris PS, et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol 2013;15(2):149-60
93. Kalushkova A, Fryknas M, Lemaire M, et al. Polycomb target genes are silenced in multiple myeloma. PLoS One 2010;5(7):e11483
94. Choudhury SR, Balasubramanian S, Chew YC, et al. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 2011;32(10):1525-32
95. Chiba T, Suzuki E, Negishi M, et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012;130(11):2557-67
96. Zhou J, Bi C, Cheong LL, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011;118(10):2830-9
97. Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009;114(13):2733-43
98. Nakagawa S, Sakamoto Y, Okabe H, et al. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Oncol Rep 2014;31(2):983-8
99. Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009;8(6):1579-88
100. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492(7427):108-12
101. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8(11):890-6
102. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012;109(52):21360-5
103. Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014;13(4):842-54
104. Keilhack H. Preclinical characterization of E7438, a potent, selective EZH2 inhibitor with robust antitumor activity against EZH2 mutated NHL xenografts in mice. Ann Oncol 2013;24:13
105. Andreoli F, Barbosa AJ, Parenti MD, et al. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des 2013;19(4):578-613
106. Kreso A, van Galen P, Pedley NM, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014;20(1):29-36
107. Kondo Y. Targeting histone methyltransferase EZH2 as cancer treatment. J Biochem 2014;156(5):249-57
108. Vandamme J, Volkel P, Rosnoblet C, et al. Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. Mol Cell Proteomics 2011;10(4):M110.002642
109. Gao Z, Zhang J, Bonasio R, et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell 2012;45(3):344-56
110. Pasini D, Bracken AP, Hansen JB, et al. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol 2007;27(10):3769-79